Supplementary Table 1 Details of subsequent initiation of antiviral therapy after recruitment (n=102)

Time to antiviral therapy (years)	5.5 (interquartile range 2.7 - 8.6)
Type of treatment	Lamivudine (n=19)
	Entecavir (n=76)
	Telbivudine (n=2)
	Clevudine (n=1)
	Adefovir (n=1)
	Tenofovir disoproxil fumarate (n=2)
	Tenofovir alanfenamide (n=1)
Indication of treatment	Hepatitis flare (n=83)
	Cirrhosis (n=15)
	Hepatocellular carcinoma (n=4)

ROC Curve

M2BPGi* and HCC development	
AUROC	0.883
95% CI	0.771 − 0.995
P value	<0.001
Cut-off	0.68 COI
Sensitivity	91.7%
Specificity	80.8%
PPV	25.8%
NPV	99.3%

AUROC: area under receiver-operating curve; CI: confidence interval; COI: cut-off index; HCC: hepatocellular carcinoma; M2BPGi: mac-2 binding protein glycosylation isomer; NPV: negative predictive value; PPV: positive predictive value; ROC: receiver-operating curve

* Baseline M2BPGi